CVS says GLP-1s save money when priced below $350 per month
AI Image

CVS says GLP-1s save money when priced below $350 per month

New York Post • • business

Key Points:

  • CVS Health's analysis of Aetna insurance claims suggests that employers and health plan sponsors could break even on GLP-1 drugs if prices are kept below $350 per month, as reduced medical service use offsets drug costs.
  • Current prices for GLP-1 drugs like Mounjaro, Ozempic, Zepbound, and Wegovy are too high to result in overall spending savings, leading some companies to drop coverage amid rising premium concerns.
  • The study found GLP-1 use linked to 10%-12% fewer emergency room visits in the first two years and a 34%-42% reduction in hospitalizations after three years, though higher drug costs still result in net increased spending at current prices.
  • CVS highlights that drugmakers could profit while lowering healthcare costs by pricing GLP-1s under $350 monthly, noting the US pays more for healthcare than any other country and referencing a government pilot paying $245 per month for Medicare beneficiaries.
  • The financial return on GLP-1 drug investment varies by patient risk profile, with higher-risk patients such as older adults with diabetes showing quicker cost savings due to reduced hospitalizations.

Trending Business

Trending Technology

Trending Health